Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|PIK3CA mutant||Advanced Solid Tumor||sensitive||MLN1117||Preclinical||Actionable||In a preclinical study, MLN1117 inhibited proliferation of tumor cells harboring oncogenic PIK3CA mutations in culture and inhibited tumor growth in PIK3CA mutant xenograft models (Cancer Ther 2011;10(11 Suppl):Abstract nr A171).||detail...|
|PIK3CA mutant||Advanced Solid Tumor||sensitive||MLN1117||Phase I||Actionable||In a Phase I trial, MLN1117 demonstrated safety and preliminary efficacy in a variety of patients with advanced solid tumors carrying PIK3CA mutations (Journal of Clinical Oncology, 2015 ASCO Annual Meeting Vol 33, No 15_suppl., 2015: 2501).||detail...|
|PubMed Id||Reference Title||Details|
|Abstract A171: A potent and selective PI3K inhibitor, INK1117, targets human cancers harboring oncogenic PIK3CA mutations.||Full reference...|
|First-in-human, phase I, dose-escalation study of selective PI3Kalpha isoform inhibitor MLN1117 in patients (pts) with advanced solid malignancies.||Full reference...|